Intrinsic value of Exelixis - EXEL

Previous Close

$17.45

  Intrinsic Value

$346.27

stock screener

  Rating & Target

str. buy

+999%

Previous close

$17.45

 
Intrinsic value

$346.27

 
Up/down potential

+999%

 
Rating

str. buy

We calculate the intrinsic value of EXEL stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 5.2

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  724
  1,119
  1,673
  2,427
  3,424
  4,708
  6,319
  8,297
  10,676
  13,485
  16,746
  20,473
  24,677
  29,361
  34,523
  40,158
  46,259
  52,815
  59,816
  67,251
  75,110
  83,386
  92,072
  101,163
  110,660
  120,562
  130,874
  141,604
  152,760
  164,355
Variable operating expenses, $m
  182
  278
  413
  596
  838
  1,150
  1,541
  2,022
  2,600
  3,282
  4,068
  4,973
  5,995
  7,132
  8,386
  9,755
  11,238
  12,830
  14,531
  16,337
  18,246
  20,257
  22,367
  24,575
  26,882
  29,288
  31,793
  34,399
  37,109
  39,926
Fixed operating expenses, $m
  179
  183
  187
  191
  195
  199
  204
  208
  213
  218
  222
  227
  232
  237
  243
  248
  253
  259
  265
  270
  276
  282
  289
  295
  302
  308
  315
  322
  329
  336
Total operating expenses, $m
  361
  461
  600
  787
  1,033
  1,349
  1,745
  2,230
  2,813
  3,500
  4,290
  5,200
  6,227
  7,369
  8,629
  10,003
  11,491
  13,089
  14,796
  16,607
  18,522
  20,539
  22,656
  24,870
  27,184
  29,596
  32,108
  34,721
  37,438
  40,262
Operating income, $m
  363
  658
  1,073
  1,640
  2,391
  3,358
  4,574
  6,067
  7,864
  9,985
  12,455
  15,272
  18,450
  21,991
  25,894
  30,155
  34,768
  39,726
  45,020
  50,643
  56,588
  62,847
  69,416
  76,293
  83,476
  90,966
  98,767
  106,883
  115,322
  124,093
EBITDA, $m
  372
  668
  1,085
  1,655
  2,409
  3,380
  4,601
  6,101
  7,906
  10,037
  12,512
  15,341
  18,533
  22,090
  26,010
  30,290
  34,924
  39,904
  45,222
  50,870
  56,841
  63,128
  69,726
  76,634
  83,849
  91,372
  99,207
  107,359
  115,836
  124,646
Interest expense (income), $m
  21
  0
  17
  44
  83
  136
  206
  295
  408
  547
  713
  910
  1,138
  1,399
  1,693
  2,021
  2,382
  2,777
  3,204
  3,663
  4,153
  4,673
  5,223
  5,802
  6,410
  7,047
  7,711
  8,404
  9,126
  9,877
  10,658
Earnings before tax, $m
  363
  641
  1,029
  1,557
  2,255
  3,153
  4,278
  5,659
  7,317
  9,272
  11,546
  14,134
  17,051
  20,298
  23,873
  27,773
  31,992
  36,522
  41,358
  46,491
  51,915
  57,624
  63,614
  69,883
  76,430
  83,255
  90,362
  97,757
  105,445
  113,435
Tax expense, $m
  98
  173
  278
  420
  609
  851
  1,155
  1,528
  1,976
  2,503
  3,117
  3,816
  4,604
  5,480
  6,446
  7,499
  8,638
  9,861
  11,167
  12,553
  14,017
  15,558
  17,176
  18,868
  20,636
  22,479
  24,398
  26,394
  28,470
  30,627
Net income, $m
  265
  468
  751
  1,137
  1,646
  2,301
  3,123
  4,131
  5,341
  6,769
  8,428
  10,318
  12,447
  14,817
  17,427
  20,274
  23,354
  26,661
  30,191
  33,938
  37,898
  42,065
  46,438
  51,015
  55,794
  60,776
  65,965
  71,362
  76,975
  82,808

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  612
  945
  1,414
  2,052
  2,895
  3,979
  5,341
  7,014
  9,025
  11,399
  14,155
  17,306
  20,860
  24,819
  29,182
  33,946
  39,103
  44,645
  50,563
  56,848
  63,491
  70,487
  77,829
  85,514
  93,542
  101,912
  110,629
  119,699
  129,129
  138,931
Adjusted assets (=assets-cash), $m
  612
  945
  1,414
  2,052
  2,895
  3,979
  5,341
  7,014
  9,025
  11,399
  14,155
  17,306
  20,860
  24,819
  29,182
  33,946
  39,103
  44,645
  50,563
  56,848
  63,491
  70,487
  77,829
  85,514
  93,542
  101,912
  110,629
  119,699
  129,129
  138,931
Revenue / Adjusted assets
  1.183
  1.184
  1.183
  1.183
  1.183
  1.183
  1.183
  1.183
  1.183
  1.183
  1.183
  1.183
  1.183
  1.183
  1.183
  1.183
  1.183
  1.183
  1.183
  1.183
  1.183
  1.183
  1.183
  1.183
  1.183
  1.183
  1.183
  1.183
  1.183
  1.183
Average production assets, $m
  73
  113
  169
  245
  346
  475
  638
  838
  1,078
  1,362
  1,691
  2,068
  2,492
  2,965
  3,487
  4,056
  4,672
  5,334
  6,041
  6,792
  7,586
  8,422
  9,299
  10,217
  11,177
  12,177
  13,218
  14,302
  15,429
  16,600
Working capital, $m
  -30
  -46
  -69
  -100
  -140
  -193
  -259
  -340
  -438
  -553
  -687
  -839
  -1,012
  -1,204
  -1,415
  -1,646
  -1,897
  -2,165
  -2,452
  -2,757
  -3,080
  -3,419
  -3,775
  -4,148
  -4,537
  -4,943
  -5,366
  -5,806
  -6,263
  -6,739
Total debt, $m
  180
  481
  902
  1,476
  2,235
  3,211
  4,437
  5,942
  7,752
  9,889
  12,369
  15,205
  18,403
  21,967
  25,894
  30,181
  34,823
  39,810
  45,136
  50,793
  56,772
  63,068
  69,676
  76,592
  83,817
  91,351
  99,196
  107,359
  115,846
  124,667
Total liabilities, $m
  551
  851
  1,273
  1,846
  2,605
  3,581
  4,807
  6,312
  8,122
  10,259
  12,740
  15,575
  18,774
  22,337
  26,264
  30,552
  35,193
  40,181
  45,507
  51,163
  57,142
  63,438
  70,046
  76,963
  84,187
  91,721
  99,566
  107,729
  116,216
  125,038
Total equity, $m
  61
  95
  141
  205
  289
  398
  534
  701
  902
  1,140
  1,416
  1,731
  2,086
  2,482
  2,918
  3,395
  3,910
  4,465
  5,056
  5,685
  6,349
  7,049
  7,783
  8,551
  9,354
  10,191
  11,063
  11,970
  12,913
  13,893
Total liabilities and equity, $m
  612
  946
  1,414
  2,051
  2,894
  3,979
  5,341
  7,013
  9,024
  11,399
  14,156
  17,306
  20,860
  24,819
  29,182
  33,947
  39,103
  44,646
  50,563
  56,848
  63,491
  70,487
  77,829
  85,514
  93,541
  101,912
  110,629
  119,699
  129,129
  138,931
Debt-to-equity ratio
  2.950
  5.080
  6.380
  7.190
  7.720
  8.070
  8.310
  8.470
  8.590
  8.680
  8.740
  8.790
  8.820
  8.850
  8.870
  8.890
  8.910
  8.920
  8.930
  8.930
  8.940
  8.950
  8.950
  8.960
  8.960
  8.960
  8.970
  8.970
  8.970
  8.970
Adjusted equity ratio
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  265
  468
  751
  1,137
  1,646
  2,301
  3,123
  4,131
  5,341
  6,769
  8,428
  10,318
  12,447
  14,817
  17,427
  20,274
  23,354
  26,661
  30,191
  33,938
  37,898
  42,065
  46,438
  51,015
  55,794
  60,776
  65,965
  71,362
  76,975
  82,808
Depreciation, amort., depletion, $m
  9
  10
  12
  15
  18
  22
  28
  34
  42
  52
  56
  69
  83
  99
  116
  135
  156
  178
  201
  226
  253
  281
  310
  341
  373
  406
  441
  477
  514
  553
Funds from operations, $m
  274
  478
  763
  1,151
  1,664
  2,324
  3,151
  4,165
  5,384
  6,820
  8,485
  10,387
  12,530
  14,916
  17,543
  20,409
  23,510
  26,839
  30,393
  34,165
  38,151
  42,346
  46,748
  51,355
  56,166
  61,182
  66,405
  71,839
  77,489
  83,361
Change in working capital, $m
  -11
  -16
  -23
  -31
  -41
  -53
  -66
  -81
  -98
  -115
  -134
  -153
  -172
  -192
  -212
  -231
  -250
  -269
  -287
  -305
  -322
  -339
  -356
  -373
  -389
  -406
  -423
  -440
  -457
  -475
Cash from operations, $m
  285
  494
  786
  1,182
  1,705
  2,376
  3,217
  4,246
  5,481
  6,936
  8,618
  10,540
  12,703
  15,108
  17,755
  20,640
  23,760
  27,108
  30,680
  34,470
  38,473
  42,685
  47,104
  51,728
  56,555
  61,588
  66,828
  72,279
  77,946
  83,836
Maintenance CAPEX, $m
  -2
  -2
  -4
  -6
  -8
  -12
  -16
  -21
  -28
  -36
  -45
  -56
  -69
  -83
  -99
  -116
  -135
  -156
  -178
  -201
  -226
  -253
  -281
  -310
  -341
  -373
  -406
  -441
  -477
  -514
New CAPEX, $m
  -27
  -40
  -56
  -76
  -101
  -130
  -163
  -200
  -240
  -284
  -329
  -376
  -425
  -473
  -521
  -569
  -616
  -662
  -707
  -751
  -794
  -836
  -877
  -918
  -959
  -1,000
  -1,042
  -1,084
  -1,127
  -1,171
Cash from investing activities, $m
  -29
  -42
  -60
  -82
  -109
  -142
  -179
  -221
  -268
  -320
  -374
  -432
  -494
  -556
  -620
  -685
  -751
  -818
  -885
  -952
  -1,020
  -1,089
  -1,158
  -1,228
  -1,300
  -1,373
  -1,448
  -1,525
  -1,604
  -1,685
Free cash flow, $m
  256
  452
  726
  1,100
  1,596
  2,235
  3,038
  4,025
  5,213
  6,616
  8,244
  10,107
  12,209
  14,552
  17,135
  19,955
  23,008
  26,290
  29,795
  33,517
  37,453
  41,597
  45,946
  50,500
  55,256
  60,215
  65,381
  70,755
  76,343
  82,151
Issuance/(repayment) of debt, $m
  180
  300
  422
  574
  759
  976
  1,226
  1,505
  1,810
  2,137
  2,480
  2,836
  3,198
  3,563
  3,927
  4,287
  4,641
  4,988
  5,326
  5,656
  5,979
  6,296
  6,608
  6,917
  7,225
  7,533
  7,845
  8,163
  8,487
  8,821
Issuance/(repurchase) of shares, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  180
  300
  422
  574
  759
  976
  1,226
  1,505
  1,810
  2,137
  2,480
  2,836
  3,198
  3,563
  3,927
  4,287
  4,641
  4,988
  5,326
  5,656
  5,979
  6,296
  6,608
  6,917
  7,225
  7,533
  7,845
  8,163
  8,487
  8,821
Total cash flow (excl. dividends), $m
  436
  752
  1,148
  1,674
  2,355
  3,211
  4,264
  5,530
  7,023
  8,753
  10,724
  12,943
  15,407
  18,115
  21,062
  24,242
  27,650
  31,278
  35,121
  39,174
  43,432
  47,893
  52,554
  57,416
  62,480
  67,749
  73,226
  78,917
  84,830
  90,972
Retained Cash Flow (-), $m
  -49
  -33
  -47
  -64
  -84
  -108
  -136
  -167
  -201
  -237
  -276
  -315
  -355
  -396
  -436
  -476
  -516
  -554
  -592
  -628
  -664
  -700
  -734
  -769
  -803
  -837
  -872
  -907
  -943
  -980
Prev. year cash balance distribution, $m
  273
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  660
  719
  1,101
  1,611
  2,270
  3,103
  4,128
  5,363
  6,822
  8,515
  10,448
  12,628
  15,052
  17,719
  20,626
  23,766
  27,134
  30,724
  34,529
  38,545
  42,768
  47,193
  51,820
  56,648
  61,678
  66,912
  72,354
  78,010
  83,887
  89,992
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  633
  658
  958
  1,326
  1,760
  2,252
  2,789
  3,352
  3,919
  4,464
  4,962
  5,389
  5,723
  5,949
  6,055
  6,039
  5,904
  5,658
  5,316
  4,898
  4,424
  3,916
  3,396
  2,885
  2,399
  1,952
  1,553
  1,207
  916
  678
Current shareholders' claim on cash, %
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0

Exelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company's cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors. The Company's CABOMETYX tablets are approved for previously treated advanced kidney cancer and COMETRIQ capsules are approved for progressive, metastatic medullary thyroid cancer. The third product, Cotellic, is a formulation of cobimetinib, a selective inhibitor of MEK is approved as part of a combination regimen to treat advanced melanoma. Both cabozantinib and cobimetinib have shown potential in a range of forms of cancer and are the subjects of broad clinical development programs. The Company's XL888 is a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein.

FINANCIAL RATIOS  of  Exelixis (EXEL)

Valuation Ratios
P/E Ratio -72.3
Price to Sales 26.5
Price to Book 56.8
Price to Tangible Book
Price to Cash Flow 24.6
Price to Free Cash Flow 24.8
Growth Rates
Sales Growth Rate 416.2%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate NaN%
Cap. Spend. - 3 Yr. Gr. Rate 0%
Financial Strength
Quick Ratio 2
Current Ratio 0
LT Debt to Equity 0%
Total Debt to Equity 212.4%
Interest Coverage -2
Management Effectiveness
Return On Assets -10.6%
Ret/ On Assets - 3 Yr. Avg. -37.5%
Return On Total Capital -25.2%
Ret/ On T. Cap. - 3 Yr. Avg. -55.8%
Return On Equity 933.3%
Return On Equity - 3 Yr. Avg. 715.5%
Asset Turnover 0.4
Profitability Ratios
Gross Margin 96.9%
Gross Margin - 3 Yr. Avg. 92.7%
EBITDA Margin -25.1%
EBITDA Margin - 3 Yr. Avg. -455.4%
Operating Margin -22%
Oper. Margin - 3 Yr. Avg. -417.2%
Pre-Tax Margin -36.6%
Pre-Tax Margin - 3 Yr. Avg. -506.2%
Net Profit Margin -36.6%
Net Profit Margin - 3 Yr. Avg. -506.2%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

EXEL stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the EXEL stock intrinsic value calculation we used $452.477 million for the last fiscal year's total revenue generated by Exelixis. The default revenue input number comes from 0001 income statement of Exelixis. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our EXEL stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for EXEL is calculated based on our internal credit rating of Exelixis, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Exelixis.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of EXEL stock the variable cost ratio is equal to 25.7%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $175 million in the base year in the intrinsic value calculation for EXEL stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 9.2% for Exelixis.

Corporate tax rate of 27% is the nominal tax rate for Exelixis. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the EXEL stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for EXEL are equal to 10.1%.

Life of production assets of 65.4 years is the average useful life of capital assets used in Exelixis operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for EXEL is equal to -4.1%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $284.961 million for Exelixis - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 296.866 million for Exelixis is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Exelixis at the current share price and the inputted number of shares is $5.2 billion.

RELATED COMPANIES Price Int.Val. Rating
BMY Bristol-Myers 53.27 71.64  hold
MRK Merck&Co 74.84 33.05  str.sell
AMGN Amgen 192.45 130.16  sell
PFE Pfizer 43.21 34.10  hold
ARRY Array BioPharm 15.71 0.01  str.sell

COMPANY NEWS

▶ Exelixis: 3Q Earnings Snapshot   [Nov-01-18 06:41PM  Associated Press]
▶ 5 Beaten-Down Biotech Stocks to Pick Up from the Wreckage   [Oct-17-18 02:27PM  InvestorPlace]
▶ Tech and biotech on collision course, squeezed by the Peninsula's limited space   [Oct-11-18 03:31PM  American City Business Journals]
▶ 3 Small Biotech Stocks to Watch in the Fourth Quarter   [Oct-07-18 01:00PM  TheStreet.com]
▶ Liver Cancers Rising - Stocks to Watch   [Oct-05-18 11:00AM  ACCESSWIRE]
▶ Top 5 Biotech Stocks for 2018   [Oct-03-18 07:33PM  Investopedia]
▶ 3 Top Mid-Cap Stocks to Buy in October   [08:21AM  Motley Fool]
▶ 3 Top Biotech Stocks to Buy Right Now   [Sep-23-18 06:33AM  Motley Fool]
▶ 7 Biotech Stocks to Buy Now   [Sep-19-18 02:38PM  InvestorPlace]
▶ Why SandRidge Energy, Sonos, and Exelixis Slumped Today   [Sep-11-18 04:56PM  Motley Fool]
▶ 3 Stocks That Could Put Apple's Returns to Shame   [Aug-31-18 01:33PM  Motley Fool]
▶ Is Beaten-Down Exelixis, Inc. a Buy Now?   [Aug-30-18 08:54AM  Motley Fool]
▶ 8 Undervalued Biotech Stocks to Watch   [Aug-20-18 10:03AM  InvestorPlace]
▶ 13 of the Cheapest Healthcare Stocks   [09:36AM  Motley Fool]
▶ Exelixis Gets the Patients Eventually   [Aug-06-18 10:30AM  Motley Fool]
▶ Here's Why Exelixis Stock Jumped Higher Today   [Aug-02-18 12:50PM  Motley Fool]
▶ Exelixis: 2Q Earnings Snapshot   [06:15PM  Associated Press]
▶ 3 Top Mid-Cap Stocks to Buy Right Now   [02:56PM  Motley Fool]
▶ 3 Top Healthcare Stocks to Buy Right Now   [Jun-28-18 08:51AM  Motley Fool]
▶ Exelixis (EXEL) Jumps: Stock Rises 8%   [Jun-27-18 08:42AM  Zacks]
▶ Why I Like Exelixis Inc (NASDAQ:EXEL)   [01:41PM  Simply Wall St.]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.